- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07698925
Diaphragmatic Breathing Exercises on Sleep Disorders un Polycystic Ovarian Syndrome
12 juli 2026 bijgewerkt door: Adly A Adam
Effect of Diaphragmatic Breathing on Sleep Disorders in Polycystic Ovarian Syndrome
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in females in reproductive age and not completely understood.
Women with PCOS appear to have an increased frequency of sleep problems.
Diaphragmatic Breathing (DB) exercises has positive effects on improving sleep quality.
The purpose of this study will evaluate the effect of diaphragmatic breathing exercises on improving sleep quality in polycystic ovarian syndrome women.
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Polycystic ovary syndrome (PCOS) is one of the most prevalent metabolic and reproductive disorders impacting women of reproductive age.
Difficulty falling asleep and maintaining sleep has been reported among women with PCOS.
Taken together, these data suggest that women with PCOS are at an increased risk for sleep disturbances, obesity and depression are associated with the increased risk.
Pharmacotherapy is only recommended for the short term.
This is particularly pertinent for women with PCOS whose insomnia and other sleep disturbances are unlikely to be short term and are related to underlying factors that need to be addressed directly.
So, there is an urgent need to a safe method for PCOS women such as diaphragmatic breathing that need further more investigations which will be conducted in this study.
Studietype
Ingrijpend
Inschrijving (Geschat)
54
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Naira H Mohamed, B.Sc
- Telefoonnummer: 010 01287797493
- E-mail: nairahesham083@gmail.com
Studie Contact Back-up
- Naam: Mai M Shehata, PHD
- Telefoonnummer: 010 01287797493
- E-mail: adampt80a@gmail.com
Studie Locaties
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypte, 11432
- Werving
- Cairo University; Faculty of Physical Therapy
-
Contact:
- Naira H Mohamed, B.Sc.
- Telefoonnummer: 010 01287797493
- E-mail: dradnanpts@gmail.com
-
Contact:
- Mai A Shehata, PHD
- Telefoonnummer: 105 01287797493
- E-mail: nairahesham083@gmail.com
-
Hoofdonderzoeker:
- Naira H Mohamed, B.Sc
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
Women aged from 25-35 years old, Diagnosed with PCOS by gynecologist, diagnosis of PCOS will be based on the 2003 Rotterdam criteria.
- They have a Pittsburgh sleep quality index (PSQI) score greater than 5.
- Not participating in any physical exercise for the previous 3 months.
- They have an insomnia severity index score greater than 15.
- They have a fatigue severity scale score greater than 36.
- Ability to use internet and phone services
Exclusion Criteria:
• Women with autoimmune diseases and cancer.
- Women with neurological, mental, cardiopulmonary and musculoskeletal disorders.
- Pregnant or lactating women.
- Women who showed regular adherence to sleeping pills, antidepressants and hormonal replacement agents.
- Inability to perform diaphragmatic breathing due to physical limitations.
- Women who participate or receive any interventions that could affect their sleep
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Study group A (Diaphragmatic breathing group)
27 participants with sleep disorders related to polycystic ovarian syndrome.
They will receive diaphragmatic breathing exercises three times per week, for 6 minutes twice a day and will receive lifestyle modification advices for 8 weeks
|
Its course is 3 times per week, 6 minutes twice a day, for 8 weeks.
When it's the first time to learn how to perform the diaphragmatic breathing technique, it's easier to follow the instructions lying down in supine position with a pillow under head.
The patient will be asked to place one hand on her abdomen, just below her ribcage, and the other hand on the middle of her chest to become aware of her diaphragm's position and function during breathing.
She will be told to breathe slowly and deeply through her nose and let her abdomen rise as much as possible.
The length of the inhalation or exhalation should be 2-3 seconds
Avoid caffeine, smoking, alcohol, napping; thirsty or hungry Regular exercising, sleep timing, relax techniques; Reduce noise, Ensure bedroom clean, no TV, mobile in bed, snack near bed, warm bath pre sleep, wear sleep cloths, most relaxed position for sleep.
|
|
Actieve vergelijker: Control Group B (Lifestyle modification advices group)
27 participants with sleep disorders related to polycystic ovarian syndrome.
They will receive lifestyle modification advices only as group (A) for 8 weeks
|
Avoid caffeine, smoking, alcohol, napping; thirsty or hungry Regular exercising, sleep timing, relax techniques; Reduce noise, Ensure bedroom clean, no TV, mobile in bed, snack near bed, warm bath pre sleep, wear sleep cloths, most relaxed position for sleep.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: Pre-treatment at baseline of the study Post-treatment after intervention completed by 8 weeks.
|
a reliable, valid, standardized measure of sleep quality, discriminate "good" and "poor" sleepers and provide an easy index for patients to complete.
It's classified into seven subcategories: "subjective sleep quality" (1 item), "sleep latency" (2 items), sleep duration (1 item), habitual sleep efficiency (3 items), sleep disturbances (7 items), use of sleeping medication (1 item), and daytime dysfunction (3 items).
Five additional questions rated by the respondent's roommate or bed partner are included for clinical purposes and are not scored, all seven-item scores were added together to generate a total score ranging from 0 to 21.
|
Pre-treatment at baseline of the study Post-treatment after intervention completed by 8 weeks.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Insomnia Severity Index (ISI)
Tijdsspanne: Pre-treatment at baseline of the study Post-treatment after intervention completed by 8 weeks.
|
A brief measure with only seven items, easily administered, All seven items are scored from 0 to 4, where higher scores indicate increasing severity of sleep disturbances and associated daytime symptoms, all seven-item scores were added together to generate a total score ranging from 0 to 28.
The ISI has been translated into multiple languages, validated in 12 countries and as a web-based measurement.
|
Pre-treatment at baseline of the study Post-treatment after intervention completed by 8 weeks.
|
|
Fatigue Assessment Scale (FAS)
Tijdsspanne: Pre-treatment at baseline of the study Post-treatment after intervention completed by 8 weeks.
|
A 10-item self-reported scale evaluating symptoms of chronic fatigue, it measures both physical and mental symptoms.
Each item of the FAS is answered using a five-point, Likert-type scale ranging from 1 ("never") to 5 ("always").
Items 4 and 10 are reverse-scored.
Total scores can range from 10, indicating the lowest level of fatigue, to 50, denoting the highest.
Since its introduction, the FAS was used in 26 different diseases or conditions, Its reliability and validity have proved to be good, the FAS is available in 20 languages and widely used
|
Pre-treatment at baseline of the study Post-treatment after intervention completed by 8 weeks.
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Studie stoel: Soheir M Elkosery, Professor, Cairo University; Faculty of Physical Therapy
- Studie directeur: Ahmed M Othman, Professor, Tanta University
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
11 juli 2026
Primaire voltooiing (Geschat)
1 september 2026
Studie voltooiing (Geschat)
30 oktober 2026
Studieregistratiedata
Eerst ingediend
8 juli 2026
Eerst ingediend dat voldeed aan de QC-criteria
10 juli 2026
Eerst geplaatst (Werkelijk)
13 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
14 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
12 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Neurologische manifestaties
- Endocriene systeemziekten
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Genitale ziekten, vrouw
- Ovariële ziekten
- Adnexale ziekten
- Gonadale aandoeningen
- Ovariële cysten
- Cysten
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Polycysteus ovarium syndroom
- Slaap-waakstoornissen
Andere studie-ID-nummers
- P.T.REC/012/005971
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .